Volume 11 Issue 4
Jul.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(4): 455-460
He Li, Li Guangming, Lin Dongdong, et al. Individualized medication of tacrolimus after liver transplantation guided by CYP3A5*1 gene polymorphisms: a prospective controlled study[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 455-460. doi: 10.3969/j.issn.1674-7445.2020.04.005
Citation: He Li, Li Guangming, Lin Dongdong, et al. Individualized medication of tacrolimus after liver transplantation guided by CYP3A5*1 gene polymorphisms: a prospective controlled study[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 455-460. doi: 10.3969/j.issn.1674-7445.2020.04.005
shu

Individualized medication of tacrolimus after liver transplantation guided by CYP3A5*1 gene polymorphisms: a prospective controlled study

doi: 10.3969/j.issn.1674-7445.2020.04.005

  • Liver Transplantation Center, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China

More Information
  • Corresponding author: Wang Lu, Email: p-p@yeah.net
  • Received Date: 2020-04-22
    Available Online: 2021-01-19
  • Publish Date: 2020-07-15
    Abstract
  •   Objective  To evaluate the safety and efficacy based on cytochrome P450(CYP)3A5*1 gene polymorphisms in guiding the individualized medication of tacrolimus (FK506) after liver transplantation.  Methods  Clinical data of 100 consecutively enrolled recipients who underwent liver transplantation for the first time were analyzed and randomly divided into experimental group and control group, with 50 cases in each group. The donors and recipients in the experimental group received preoperative CYP3A5 gene detection, and determined the FK506 medication regimen according to the CYP3A5*1 genotype. The compliance rate of FK506 target blood concentration, the recovery rate of liver function in the two groups of recipients at 7, 14, 28 d and 3, 6, 9, 12 months postoperatively, as well as the number of FK506 dosage adjustment during the follow-up were observed. The 1-year graft survival rate and the incidence of complications were recorded in both groups of recipients, such as acute rejection, infection, acute kidney injury, gastrointestinal symptoms, de novo hypertension, de novo diabetes, colds and rash, etc.  Results  The differences of the compliance rate of FK506 target blood concentration between the two groups of recipients at 7, 14 d after operation were statistically significant (both P < 0.05). There was no statistically significant difference between the two groups in the compliance rate of FK506 target blood concentration at 28 d and 3, 6, 9, 12 months and the recovery rate of liver function at the 7 observation time points after operation (all P > 0.05). The difference between the two groups of recipients in number of FK506 dose adjustment during follow-up was statistically significant (P=0.021). There were no statistically significant differences in 1-year graft survival rate and incidence of complications between the two groups of recipients after operation and during follow-up (all P > 0.05).  Conclusions  It is safe to guide individualized medication of FK506 after liver transplantation according to CYP3A5*1 gene polymorphism. It can increase the compliance rate of FK506 target blood concentration of recipients in the early postoperative stage, and can effectively reduce the number of dose adjustment duringfollow-up.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    HRYNIEWIECKA E, ZEGARSKA J, ZOCHOWSKA D, et al. Lack of relationship between renal function and genetic variants of CYP3A4, CYP3A5, MDR1, MRP2, UGT1A9, UGT1A8, and UGT2B7 in patients after liver transplantation in a 2-year follow-up[J]. Transplant Proc, 2020, DOI: 10.1016/j.transproceed.2020.01.096[Epubahead of print].
    [2]
    TOGASHI J, AKAMASTU N, KOKUDO N. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital[J]. Hepatobiliary Surg Nutr, 2016, 5(5):399-407. doi: 10.21037/hbsn.2016.08.05
    [3]
    JAIN A, DOPPALAPUDI S, DOMB AJ, et al. Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis[J]. J Control Release, 2016, 243:132-145. DOI: 10.1016/j.jconrel. 2016.10.004.
    [4]
    KUYPERS DR. "What do we know about tacrolimus pharmacogenetics in transplant recipients?"[J]. Pharmacogenomics, 2018, 19(7):593-597. DOI: 10.2217/pgs-2018-0035.
    [5]
    DEBETTE-GRATIEN M, WOILLARD JB, PICARD N, et al. Influence of donor and recipient CYP3A4, CYP3A5, and ABCB1 genotypes on clinical outcomes and nephrotoxicity in liver transplant recipients[J]. Transplantation, 2016, 100(10):2129-2137. doi: 10.1097/TP.0000000000001394
    [6]
    WANG YQ, WANG CH, ZHANG JH. Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis[J]. Thromb Res, 2016, 147:1-6. DOI: 10.1016/j.thromres.2016.09.016.
    [7]
    CAMPAGNE O, MAGER DE, TORNATORE KM. Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?[J]. J Clin Pharmacol, 2019, 59(3):309-325. DOI: 10.1002/jcph.1325.
    [8]
    江佳, 刘俊, 汪琳, 等.异基因造血干细胞移植受者CYP3A4及CYP3A5基因多态性对他克莫司血药浓度及疗效的影响[J].安徽医药, 2018, 22(2):344-347.DOI: 10.3969/j.issn.1009-6469.2018.02.040.

    JIANG J, LIU J, WANG L, et al. Effect of CYP3A4 and CYP3A5 genetic polymorphism on blood concentration and efficacy of tacrolimus in patients with allogeneic hematopoietic stem cell transplantation[J]. Anhui Med Pharm J, 2018, 22(2):344-347. DOI: 10.3969/j.issn.1009-6469. 2018.02.040.
    [9]
    CZERWIŃSKI M, AMUNOM I, PIRYATINSKY V, et al. Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro[J]. Pharmacol Res Perspect, 2018, 6(3):e00397. DOI: 10.1002/prp2.397.
    [10]
    CHAN SW, XIAO Y, HU M, et al. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese[J]. J Clin Pharm Ther, 2016, 41(5):552-558. DOI: 10.1111/jcpt.12433.
    [11]
    MIYATA Y, AKAMATSU N, SUGAWARA Y, et al. Pharmacokinetics of a once-daily dose of tacrolimus early after liver transplantation: with special reference to CYP3A5 and ABCB1 single nucleotide polymorphisms[J]. Ann Transplant, 2016, 21:491-499. doi: 10.12659/AOT.898358
    [12]
    ABO EL FOTOH WM, ABD EL NABY SA, HABIB MS, et al. The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children[J]. Seizure, 2016, 41:75-80. DOI: 10.1016/j.seizure.2016.07.005.
    [13]
    ITOHARA K, YANO I, TSUZUKI T, et al. A minimal physiologically-based pharmacokinetic model for tacrolimus in living-donor liver transplantation: perspectives related to liver regeneration and the cytochrome P450 3A5 (CYP3A5) genotype[J]. CPT Pharmacometrics Syst Pharmacol, 2019, 8(8):587-595. DOI: 10.1002/psp4.12420.
    [14]
    ADEAGBO BA, BOLAJI OO, OLUGBADE TA, et al. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia[J]. J Clin Pharm Ther, 2016, 41(5):546-551. DOI: 10.1111/jcpt.12424.
    [15]
    MIYAUCHI E, TACHIKAWA M, DECLÈVES X, et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects[J]. Mol Pharm, 2016, 13(8):2631-2640. DOI: 10.1021/acs.molpharmaceut. 6b00085.
    [16]
    KUEHL P, ZHANG J, LIN Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4):383-391. doi: 10.1038/86882
    [17]
    DENG R, LIAO Y, LI Y, et al. Association of CYP3A5, CYP2C8, and ABCB1 polymorphisms with early renal injury in Chinese liver transplant recipients receiving tacrolimus[J]. Transplant Proc, 2018, 50(10):3258-3265. DOI: 10.1016/j.transproceed.2018.06.040.
    [18]
    HENDERSON LM, CLAW KG, WOODAHL EL, et al. P450 pharmacogenetics in indigenous north American populations[J]. J Pers Med, 2018, 8(1): E9. DOI: 10.3390/jpm8010009.
    [19]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会.中国肝癌肝移植临床实践指南(2018版)[J].临床肝胆病杂志, 2019, 35(2):275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018 edition)[J]. J Clin Hepatol, 2019, 35 (2):275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [20]
    MIN S, PAPAZ T, LAFRENIERE-ROULA M, et al. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation[J]. Pediatr Transplant, 2018, 22(7):e13285. DOI: 10.1111/petr.13285.
    [21]
    FANG Y, GAO J, WANG T, et al. Intraindividual variation and correlation of cytochrome P450 activities in human liver microsomes[J]. Mol Pharm, 2018, 15(11):5312-5318. DOI: 10.1021/acs.molpharmaceut.8b00787.
    [22]
    OU B, LIU Y, ZHANG T, et al. TLR9 rs352139 genetic variant promotes tacrolimus elimination in Chinese liver transplant patients during the early posttransplantation period[J]. Pharmacotherapy, 2019, 39(1):67-76. DOI: 10.1002/phar.2204.
    [23]
    SIBULESKY L, LI M, HANSEN RN, et al. Impact of cold ischemia time on outcomes of liver transplantation: a single center experience[J]. Ann Transplant, 2016, 21:145-151. doi: 10.12659/AOT.896190
    [24]
    中华医学会器官移植学分会.器官移植免疫抑制剂临床应用技术规范(2019版)[J].器官移植, 2019, 10(3):213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical application of immunosuppressive agents in organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(3):213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
    [25]
    JI E, KIM MG, OH JM. CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation[J]. Ther Clin Risk Manag, 2018, 14:2119-2126. DOI: 10.2147/TCRM.S184376.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (187) PDF downloads(34) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return